exit · SE · 16 APR 2026SAGA Diagnostics, acquisition by Roche for EUR 535.5M.SAGA Diagnostics · EUR 535.5MProvenanceSourcesfiercebiotech.comhttps://www.fiercebiotech.com/medtech/roche-boosts-diagnostics-offering-595m-saga-buyoutActivityMore from SAGA DiagnosticsFunding · 29 Jun · EUR 10.4MSAGA Diagnostics raised a SEK 106 million (about EUR 10.5 million) Series A2 round led by Segulah Medical Acceleration and the Sciety investment syndicate with support from existing shareholder Hadean Ventures, to commercialize its liquid biopsy cancer tests. This predates the April 2026 Foundation Medicine/Roche acquisition already on record.